https://www.biovaxys.com https://www.biovaxys.com/contact https://www.biovaxys.com/filings https://www.biovaxys.com/governance https://www.biovaxys.com/investors https://www.biovaxys.com/newsroom https://www.biovaxys.com/stock-information https://www.biovaxys.com/dpx https://www.biovaxys.com/newsroom/aliquam-autem-perspiciatis https://www.biovaxys.com/newsroom/appointment-of-new-director https://www.biovaxys.com/newsroom/bio-manufacturing-partner-bioelpida-completes-next-phase-of-bvx-0918-gmp-production-for-eu-clinical-study https://www.biovaxys.com/newsroom/biovaxys-acquires-all-intellectual-property-immunotherapeutics-platform-technology-and-clinical-stage-assets-of-the-former-imv-inc https://www.biovaxys.com/newsroom/biovaxys-acquires-clinical-study-management-company-and-completes-private-placement https://www.biovaxys.com/newsroom/biovaxys-and-bioelpida-sign-definitive-exclusive-agreement-to-begin-ovarian-cancer-vaccine-bioproduction https://www.biovaxys.com/newsroom/biovaxys-and-bioproduction-partner-bio-elpida-begin-construction-of-gmp-facility-to-produce-clinical-supply-for-planned-ovarian-cancer-vaccine-study https://www.biovaxys.com/newsroom/biovaxys-and-horizon-technology-finance-corp-execute-amendment-to-asset-purchase-agreement-apa-2 https://www.biovaxys.com/newsroom/biovaxys-and-horizon-technologyfinance-corp-execute-amendment-to-asset-purchase-agreement-apa https://www.biovaxys.com/newsroom/biovaxys-and-procare-health-agree-to-termination-of-usa-distribution-agreement-for-papilocare https://www.biovaxys.com/newsroom/biovaxys-and-procare-health-announce-broad-co-development-joint-commercialization-and-marketing-collaboration-for-cancer-and-viral-vaccines https://www.biovaxys.com/newsroom/biovaxys-and-sona-nanotech-enter-research-collaboration https://www.biovaxys.com/newsroom/biovaxys-and-spayvac-for-wildlife-expand-license-agreement-into-commercial-aquaculture https://www.biovaxys.com/newsroom/biovaxys-and-spayvac-for-wildlife-inc-announce-launch-of-field-trial-for-large-scale-immunocontraception-in-the-commercial-aquatic-farming-industry https://www.biovaxys.com/newsroom/biovaxys-and-spayvac-for-wildlife-inc-announce-launch-of-trial-to-test-immunocontraception-in-asian-elephants https://www.biovaxys.com/newsroom/biovaxys-and-the-ohio-state-university-enter-into-sars-cov-2-research-collaboration-to-study-new-vaccine https://www.biovaxys.com/newsroom/biovaxys-and-the-ohio-state-university-extend-research-collaboration https://www.biovaxys.com/newsroom/biovaxys-and-the-ohio-state-university-progress-pan-sarbecovirus-vaccine-research-program https://www.biovaxys.com/newsroom/biovaxys-and-the-world-ovarian-cancer-coalition-join-forces-for-may-8th-world-ovarian-cancer-day https://www.biovaxys.com/newsroom/biovaxys-announces-96-4-percent-positive-antibody-immune-response-results-from-an-in-vivo-murine-model-study-of-its-sars-cov-2-vaccine https://www.biovaxys.com/newsroom/biovaxys-announces-allowance-of-dpx-formulation-patent-for-the-united-states-and-filing-of-additional-international-patent-applications-for-phase-1-dpx-surmage https://www.biovaxys.com/newsroom/biovaxys-announces-allowance-of-dpx-related-patent-for-japan-and-filing-of-additional-international-patent-applications https://www.biovaxys.com/newsroom/biovaxys-announces-amended-life-offering https://www.biovaxys.com/newsroom/biovaxys-announces-appointment-of-cfo-and-board-changes https://www.biovaxys.com/newsroom/biovaxys-announces-appointment-of-policy-advisor https://www.biovaxys.com/newsroom/biovaxys-announces-broadening-of-share-liquidity-with-dtcc-full-service-eligibility https://www.biovaxys.com/newsroom/biovaxys-announces-bvx-0320-poster-presentation-at-isirv-who-virtual-conference https://www.biovaxys.com/newsroom/biovaxys-announces-closing-of-unsecured-convertible-debenture-offering https://www.biovaxys.com/newsroom/biovaxys-announces-complete-inhibition-of-ace-2-binding-activity-of-hapten-modified-sars-cov-2-protein https://www.biovaxys.com/newsroom/biovaxys-announces-completed-debt-settlement https://www.biovaxys.com/newsroom/biovaxys-announces-completed-debt-settlement-2 https://www.biovaxys.com/newsroom/biovaxys-announces-completed-debt-settlement-3 https://www.biovaxys.com/newsroom/biovaxys-announces-completed-private-placement-and-debt-settlement https://www.biovaxys.com/newsroom/biovaxys-announces-completed-synthesis-of-its-pan-sarbecovirus-vaccine-candidate-and-launch-of-in-vivo-animal-study https://www.biovaxys.com/newsroom/biovaxys-announces-completion-of-first-tranche-of-private-placement https://www.biovaxys.com/newsroom/biovaxys-announces-consolidation-and-concurrent-brokered-private-placement-offering-for-gross-proceeds-of-up-to-3-000-000 https://www.biovaxys.com/newsroom/biovaxys-announces-conversion-of-debentures https://www.biovaxys.com/newsroom/biovaxys-announces-conversion-of-debentures-f2ddb https://www.biovaxys.com/newsroom/biovaxys-announces-debt-settlement https://www.biovaxys.com/newsroom/biovaxys-announces-extension-of-life-offering-closing-date https://www.biovaxys.com/newsroom/biovaxys-announces-initiation-of-cancer-vaccine-eu-clinical-program-completion-of-bvx-0320-preclinical-program https://www.biovaxys.com/newsroom/biovaxys-announces-interim-results-from-preclinical-study-of-its-sars-cov-2-vaccine https://www.biovaxys.com/newsroom/biovaxys-announces-issuance-of-dpx-related-patent-from-the-u-s-patent-and-trademark-office https://www.biovaxys.com/newsroom/biovaxys-announces-life-offering https://www.biovaxys.com/newsroom/biovaxys-announces-major-research-collaboration-with-the-ohio-state-university-to-develop-broadly-reactive-pan-sarbecovirus-vaccine https://www.biovaxys.com/newsroom/biovaxys-announces-management-change https://www.biovaxys.com/newsroom/biovaxys-announces-new-chief-financial-officer https://www.biovaxys.com/newsroom/biovaxys-announces-non-brokered-private-placement https://www.biovaxys.com/newsroom/biovaxys-announces-non-brokered-private-placement-2 https://www.biovaxys.com/newsroom/biovaxys-announces-planned-private-placement https://www.biovaxys.com/newsroom/biovaxys-announces-planned-private-placement-and-debt-settlement https://www.biovaxys.com/newsroom/biovaxys-announces-positive-phase-1-clinical-study-results-with-maveropepimut-s-mvp-s-in-women-with-hormone-receptor-positive-her2-negative-hr-her2--stage-ii-iii-breast-cancer-97191 https://www.biovaxys.com/newsroom/biovaxys-announces-private-placement-offering https://www.biovaxys.com/newsroom/biovaxys-announces-proposed-debt-settlement https://www.biovaxys.com/newsroom/biovaxys-announces-results-from-the-ohio-state-university-pan-sarbecovirus-animal-study https://www.biovaxys.com/newsroom/biovaxys-announces-revocation-of-cease-trade-order-and-expansion-of-cancer-vaccine-platform-patent-portfolio https://www.biovaxys.com/newsroom/biovaxys-announces-sale-of-taet-software-co https://www.biovaxys.com/newsroom/biovaxys-announces-share-consolidation https://www.biovaxys.com/newsroom/biovaxys-announces-shareholder-meeting-results https://www.biovaxys.com/newsroom/biovaxys-announces-successful-test-run-production-of-its-bi-haptenized-ovarian-cancer-vaccine https://www.biovaxys.com/newsroom/biovaxys-announces-that-covidth-demonstrates-safety-and-tolerability-in-broad-ranging-in-vivo-clinical-pathology-immunology-and-histopathology-evaluation https://www.biovaxys.com/newsroom/biovaxys-announces-unsecured-convertible-debenture-offering-and-cancellation-of-brokered-life-offering https://www.biovaxys.com/newsroom/biovaxys-announces-uplisting-to-the-octqb-venture-market https://www.biovaxys.com/newsroom/biovaxys-announces-upsizing-of-life-offering-of-up-to-2m https://www.biovaxys.com/newsroom/biovaxys-announces-warrant-extension https://www.biovaxys.com/newsroom/biovaxys-appoints-christopher-cherry-as-chief-financial-officer https://www.biovaxys.com/newsroom/biovaxys-appoints-former-sanofi-vaccines-executive-to-board-of-directors https://www.biovaxys.com/newsroom/biovaxys-assigned-bvaxf-by-finra-as-new-us-otc-trading-symbol https://www.biovaxys.com/newsroom/biovaxys-begins-toxicity-study-ahead-of-covidth-ind-submission https://www.biovaxys.com/newsroom/biovaxys-bioproduction-partner-wuxi-biologics-completes-synthesis-of-recombinant-sars-cov-2-s-proteins-for-bvx-0320-and-covidth-programs https://www.biovaxys.com/newsroom/biovaxys-broadens-intellectual-property-portfolio https://www.biovaxys.com/newsroom/biovaxys-cancer-vaccine-manufacturing-partner-bio-elpida-reaches-bioproduction-milestone https://www.biovaxys.com/newsroom/biovaxys-closes-final-tranche-of-non-brokered-private-placement https://www.biovaxys.com/newsroom/biovaxys-closes-first-tranche-of-non-brokered-private-placement https://www.biovaxys.com/newsroom/biovaxys-closes-first-tranche-of-non-brokered-private-placement-2 https://www.biovaxys.com/newsroom/biovaxys-co-founder-and-chief-medical-officer-david-berd-md-to-present-at-world-vaccine-immunotherapy-congress-west-coast-2021 https://www.biovaxys.com/newsroom/biovaxys-completes-the-acquisition-of-all-intellectual-property-immunotherapeutics-platform-technology-and-clinical-stage-assets-of-the-former-imv-inc https://www.biovaxys.com/newsroom/biovaxys-confirms-first-clinical-site-and-principal-investigators-for-ovarian-cancer-vaccine-trial-and-enters-into-second-tumor-cell-supply-agreement https://www.biovaxys.com/newsroom/biovaxys-dpx-based-vaccines-exhibit-robust-efficacy-across-multiple-infectious-diseases https://www.biovaxys.com/newsroom/biovaxys-dpx-exhibits-superior-immune-system-activation-compared-to-aqueous-and-emulsion-based-antigen-delivery-systems https://www.biovaxys.com/newsroom/biovaxys-engages-enclave-capital-llc-to-act-as-an-agent-in-brokered-private-placement-offering https://www.biovaxys.com/newsroom/biovaxys-engages-life-sciences-public-relations-and-market-communications-firm-6-degrees https://www.biovaxys.com/newsroom/biovaxys-enters-critical-tumor-cell-supply-agreement-with-deaconess-research-institute-for-bvx-0918-bioproduction https://www.biovaxys.com/newsroom/biovaxys-enters-major-bioproduction-agreement-with-wuxi-biologics-hong-kong-ltd-to-synthesize-proteins-for-its-sars-cov-2-vaccine-and-covid-t-immunodiagnostic-programs https://www.biovaxys.com/newsroom/biovaxys-executes-binding-term-sheet-for-the-us-marketing-distribution-for-papilocare-gel-and-oral-immunocaps https://www.biovaxys.com/newsroom/biovaxys-executes-letter-of-intent-for-major-immunotherapeutics-technology-acquisition https://www.biovaxys.com/newsroom/biovaxys-expanding-technology-platform-to-address-emerging-sars-cov-2-variants https://www.biovaxys.com/newsroom/biovaxys-expands-cancer-vaccine-platform https://www.biovaxys.com/newsroom/biovaxys-files-fda-pre-ind-meeting-request-and-briefing-package-for-covid-t https://www.biovaxys.com/newsroom/biovaxys-files-patent-application-for-novel-covid-19-diagnostic-for-t-cell-immunity https://www.biovaxys.com/newsroom/biovaxys-files-us-patent-application-for-pan-sarbecovirus-vaccine https://www.biovaxys.com/newsroom/biovaxys-further-expands-intellectual-property-portfolio-in-global-markets https://www.biovaxys.com/newsroom/biovaxys-further-expands-vaccines-intellectual-property-portfolio https://www.biovaxys.com/newsroom/biovaxys-issues-corporate-update https://www.biovaxys.com/newsroom/biovaxys-licensee-spayvac-for-wildlife-inc-reports-further-positive-single-dose-efficacy-data-for-its-immunocontraceptive-vaccine-and-initiation-of-regulatory-submission-process https://www.biovaxys.com/newsroom/biovaxys-partner-spayvac-for-wildlife-inc-scales-up-vaccine-production-capacity https://www.biovaxys.com/newsroom/biovaxys-prepares-for-groundbreaking-study-on-reduced-ace2-binding-capabilities-of-hapten-modified-sars-cov-2-proteins https://www.biovaxys.com/newsroom/biovaxys-provides-viral-vaccine-platform-program-update https://www.biovaxys.com/newsroom/biovaxys-receives-positive-fda-response-for-pre-ind-review-for-covidth-clinical-development https://www.biovaxys.com/newsroom/biovaxys-reports-agm-results https://www.biovaxys.com/newsroom/biovaxys-retains-maxim-group-as-financial-advisor-and-investment-banker https://www.biovaxys.com/newsroom/biovaxys-shares-new-data-on-its-dpx-tm-immune-educating-platform-at-personalized-cancer-vaccine-summit https://www.biovaxys.com/newsroom/biovaxys-strengthens-internal-expertise-with-appointment-of-scientific-advisor-for-ovarian-cancer-vaccine-clinical-program-and-papilocare-marketing https://www.biovaxys.com/newsroom/biovaxys-technology-corp-announces-revocation-of-cease-trade-order https://www.biovaxys.com/newsroom/biovaxys-technology-corp-closes-first-tranche-of-private-placement https://www.biovaxys.com/newsroom/biovaxys-technology-corp-closes-second-tranche-of-private-placement https://www.biovaxys.com/newsroom/biovaxys-technology-corp-granted-voluntary-management-cease-trade-order https://www.biovaxys.com/newsroom/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update https://www.biovaxys.com/newsroom/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-2 https://www.biovaxys.com/newsroom/biovaxys-to-participate-in-the-us-government-biomedical-advanced-research-and-development-authority-barda-rapid-response-partnership-vehicle-rrpv-vaccine-development-consortium https://www.biovaxys.com/newsroom/clinical-study-collaborator-hcl-sends-first-surgically-excised-ovarian-cancer-tumors-to-biovaxys-for-bvx-0918-vaccine-process-development https://www.biovaxys.com/newsroom/clinical-trial-affirms-covidth-diagnostic-approach-to-screen-for-t-cell-mediated-immune-response-to-sars-cov-2-is-safe-and-effective-in-humans https://www.biovaxys.com/newsroom/director-made-an-order-under-paragraphs-2-and-2-1-of-subsection-127-1 https://www.biovaxys.com/newsroom/fda-provides-necessary-guidance-for-biovaxys-to-begin-preparation-of-ind-for-phase-i-ii-clinical-trials-of-covidth https://www.biovaxys.com/newsroom/further-study-in-humans-shows-that-the-dth-response-the-basis-for-covidth-is-highly-durable-and-persists-for-at-least-one-year-after-covid-19-exposure-or-vaccine-administration https://www.biovaxys.com/newsroom/lions-bay-announces-closing-of-final-tranche-of-non-brokered-private-placement-and-provides-update-on-completion-of-production-and-start-of-dosing-in-biovaxys-preclincal-study-of-sars-cov-2-vaccine https://www.biovaxys.com/newsroom/lions-bay-announces-definitive-agreement-for-biovaxys-acquisition-and-concurrent-financing https://www.biovaxys.com/newsroom/lions-bay-mining-announces-update-on-acquisition-target-biovaxys https://www.biovaxys.com/newsroom/spayvac-for-wildlife-inc-announces-completion-of-spayvac-r-research-and-production-facility-in-madison-wisconsin https://www.biovaxys.com/newsroom/thomas-jefferson-university-and-biovaxys-llc-enter-into-exclusive-worldwide-license